ArticleInternational journal of spine surgery2026
Index Hospital Costs and Postoperative Outcomes of Lumbar Spine Fusion With FIBERGRAFT Vs Bone Morphogenic Protein-2: A Propensity Score-Matched Analysis.
Article in International journal of spine surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are limited data available to understand the value of bioactive glass for spinal fusion procedures. Bone morphogenic protein-2 (BMP-2) is an established graft that has been on the market for roughly 24 years, while bioactive glass represents a newer class of graft technology. The objective of this study is to compare economic, health care utilization, and postoperative outcomes associated with the use of a bioactive glass vs BMP-2.
methodsA retrospective, comparative study was conducted to compare a bioactive glass, FIBERGRAFT (DePuy Synthes, Raynham, MA), to BMP-2. The Premier hospital billing database was used. Patients who underwent lumbar fusion from 2016 to 2024 with bioactive glass or BMP-2 were included. The primary study outcome was index hospital cost. The exploratory outcomes were length of stay, operation room time, and 1-year pseudarthrosis, spinal infection overall (defined as the presence of spinal infection or surgical site infection), and surgical site infection only. Patients in each graft group were balanced using propensity score matching. Analyses were conducted for the overall cohort (primary) and, as a sensitivity analysis, for a subset of patients based on primary procedure and diagnosis.
resultsThe group sizes for each cohort before balancing were 1,013 and 59,394 patients for bioactive glass and BMP-2, respectively. After matching, the group sizes for both grafts were 1013 patients for a total of 2026 patients in the matched cohort. In the matched cohort, 65 to 74 years was the most frequent age group (34% in each cohort), and more than half were women (57% bioactive glass, 56% BMP-2). The mean (95% CI) index hospital costs were $40,187 ($39,132, $41,241) for bioactive glass and $45,010 ($43,809, $46,211) for BMP-2, representing a mean difference (95% CI) of -$4823 ($-6382, $-3265),
conclusionThis study suggests that patients who undergo lumbar fusion with bioactive glass have lower index costs and similar health care resource utilization and postoperative outcomes compared with those who receive BMP-2. Results from this study may help payers, health care systems, and providers make value-based decisions regarding product utilization. CLINICAL RELEVANCE: This research provides an understanding of hospital costs, health care resource utilization, and 1-year outcomes of bioactive glass used in lumbar fusion surgery using a comparative study design. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.